MX2018011839A - Constructos de alfavirus vivo atenuado y metodos y usos de los mismos. - Google Patents

Constructos de alfavirus vivo atenuado y metodos y usos de los mismos.

Info

Publication number
MX2018011839A
MX2018011839A MX2018011839A MX2018011839A MX2018011839A MX 2018011839 A MX2018011839 A MX 2018011839A MX 2018011839 A MX2018011839 A MX 2018011839A MX 2018011839 A MX2018011839 A MX 2018011839A MX 2018011839 A MX2018011839 A MX 2018011839A
Authority
MX
Mexico
Prior art keywords
live
methods
attenuated
constructs
alphaviruses
Prior art date
Application number
MX2018011839A
Other languages
English (en)
Spanish (es)
Inventor
Ann Livengood Jill
Duane Powell Timothy
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2018011839A publication Critical patent/MX2018011839A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161Methods of inactivation or attenuation
    • C12N2770/36162Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2018011839A 2016-03-31 2017-03-28 Constructos de alfavirus vivo atenuado y metodos y usos de los mismos. MX2018011839A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316264P 2016-03-31 2016-03-31
PCT/US2017/024450 WO2017172698A1 (en) 2016-03-31 2017-03-28 Live, attenuated alphavirus constructs and methods and uses thereof

Publications (1)

Publication Number Publication Date
MX2018011839A true MX2018011839A (es) 2019-05-23

Family

ID=58501809

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011839A MX2018011839A (es) 2016-03-31 2017-03-28 Constructos de alfavirus vivo atenuado y metodos y usos de los mismos.

Country Status (17)

Country Link
US (1) US20190106682A1 (enExample)
EP (1) EP3436062A1 (enExample)
JP (1) JP2019509750A (enExample)
KR (1) KR20180135913A (enExample)
CN (1) CN109195625A (enExample)
AU (1) AU2017241669A1 (enExample)
BR (1) BR112018069079A2 (enExample)
CA (1) CA3019536A1 (enExample)
CO (1) CO2018010359A2 (enExample)
CR (1) CR20180457A (enExample)
DO (1) DOP2018000209A (enExample)
EC (1) ECSP18081582A (enExample)
MX (1) MX2018011839A (enExample)
PE (1) PE20190178A1 (enExample)
PH (1) PH12018502120A1 (enExample)
SG (1) SG11201808479VA (enExample)
WO (1) WO2017172698A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020024292A2 (pt) * 2018-06-06 2021-03-02 Massachusetts Institute Of Technology rna circular para translação em células eucarióticas
CN110213711B (zh) * 2019-04-22 2021-06-18 腾讯科技(深圳)有限公司 一种常驻点的估计方法、装置、设备和介质
CN114561366B (zh) * 2022-03-30 2023-06-20 西南民族大学 一种山羊库布病毒分离株及其应用
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
CN117925540B (zh) * 2024-03-22 2024-06-18 北京昭衍新药研究中心股份有限公司 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用
CN118127077B (zh) * 2024-05-08 2024-07-16 南京农业大学三亚研究院 基于盖塔病毒骨架的嵌合甲病毒制备方法和应用
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
KR101668849B1 (ko) * 2008-01-24 2016-10-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도

Also Published As

Publication number Publication date
KR20180135913A (ko) 2018-12-21
ECSP18081582A (es) 2019-02-28
SG11201808479VA (en) 2018-10-30
CO2018010359A2 (es) 2018-12-14
AU2017241669A1 (en) 2018-11-22
CN109195625A (zh) 2019-01-11
EP3436062A1 (en) 2019-02-06
PH12018502120A1 (en) 2019-07-15
DOP2018000209A (es) 2019-01-31
CA3019536A1 (en) 2017-10-05
CR20180457A (es) 2019-04-09
US20190106682A1 (en) 2019-04-11
PE20190178A1 (es) 2019-02-01
BR112018069079A2 (pt) 2019-01-29
JP2019509750A (ja) 2019-04-11
WO2017172698A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
ZA202403393B (en) Synthetic chimeric poxviruses
EP4349405A3 (en) Respiratory virus vaccines
EP4218807A3 (en) Zika virus vaccine
EA201800108A1 (ru) Вакцинные композиции для профилактики абровирусных инфекций
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
EP4043031A3 (en) Zika viral antigen constructs
MY194449A (en) Zika vaccines and immunogenic compositions, and methods of using the same
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EP4252681A3 (en) Implantable objects, guiding devices, and methods of use thereof
BR112015023332A2 (pt) Toxóide, composições e método relacionados
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
WO2016100615A3 (en) Methods and composition for neutralization of influenza
MX2016004078A (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
PH12015502115A1 (en) Compositions and methods for live, attenuated alphavirus formulations
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
PH12018502119A1 (en) Compositions and methods for stabilizing alphaviruses with improved formulations
MX2022010827A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.